loading
Precedente Chiudi:
$11.23
Aprire:
$11.14
Volume 24 ore:
13,987
Relative Volume:
0.02
Capitalizzazione di mercato:
$768.33M
Reddito:
-
Utile/perdita netta:
$-209.96M
Rapporto P/E:
-3.8215
EPS:
-2.97
Flusso di cassa netto:
$-176.27M
1 W Prestazione:
-1.14%
1M Prestazione:
-0.70%
6M Prestazione:
+102.33%
1 anno Prestazione:
+8.05%
Intervallo 1D:
Value
$11.14
$11.28
Intervallo di 1 settimana:
Value
$10.57
$11.50
Portata 52W:
Value
$4.92
$12.97

Replimune Group Inc Stock (REPL) Company Profile

Name
Nome
Replimune Group Inc
Name
Telefono
(781) 222-9600
Name
Indirizzo
500 UNICORN PARK, WOBURN, MA
Name
Dipendente
331
Name
Cinguettio
@Replimune
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
REPL's Discussions on Twitter

Confronta REPL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
REPL 11.28 768.33M 0 -209.96M -176.27M -2.97
VRTX 446.63 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.99 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.16 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.33 24.49B 3.30B -501.07M 1.03B 11.54

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-04-17 Ripresa Piper Sandler Overweight
2021-11-19 Iniziato Piper Sandler Overweight
2021-10-15 Ripresa BTIG Research Buy
2020-11-17 Iniziato BTIG Research Buy
2020-11-02 Iniziato Jefferies Buy
2020-10-15 Aggiornamento H.C. Wainwright Neutral → Buy
2020-07-01 Downgrade H.C. Wainwright Buy → Neutral
2020-05-05 Iniziato Barclays Overweight
2019-09-04 Iniziato ROTH Capital Buy
2019-07-23 Iniziato Chardan Capital Markets Buy
2019-07-12 Aggiornamento JP Morgan Neutral → Overweight
2019-07-08 Iniziato H.C. Wainwright Buy
2019-04-25 Iniziato Wedbush Outperform
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-08-14 Iniziato JP Morgan Overweight
2018-08-14 Iniziato Leerink Partners Outperform
Mostra tutto

Replimune Group Inc Borsa (REPL) Ultime notizie

pulisher
12:53 PM

Replimune's chief commercial officer sells $56,131 in stock By Investing.com - Investing.com Nigeria

12:53 PM
pulisher
Nov 20, 2024

Replimune group's chief medical officer sells shares worth $78,111 By Investing.com - Investing.com Canada

Nov 20, 2024
pulisher
Nov 20, 2024

Replimune's chief commercial officer sells $56,131 in stock - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

REPL (Replimune Group) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP - MarketBeat

Nov 20, 2024
pulisher
Nov 17, 2024

Replimune Group Q3 EPS Forecast Decreased by Leerink Partnrs - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Predicts Stronger Earnings for Replimune Group - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Weighs in on Replimune Group Q3 Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Significant Stake Increase by Baker Bros. Advisors in Replimune Group Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80 - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 13, 2024

Replimune Group’s Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Replimune Group Inc. (REPL) Quarterly 10-Q Report - Quartzy

Nov 13, 2024
pulisher
Nov 12, 2024

Replimune Group (NASDAQ:REPL) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Replimune Reports $432.1M Cash Position, Advances Melanoma Treatment BLA Plans | REPL Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Replimune stock soars to 52-week high, touches $12.86 By Investing.com - Investing.com Australia

Nov 12, 2024
pulisher
Nov 12, 2024

Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.80 - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Replimune stock soars to 52-week high, touches $12.86 - Investing.com India

Nov 11, 2024
pulisher
Nov 11, 2024

Replimune Group (NASDAQ:REPL) Hits New 52-Week HighStill a Buy? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Creative Planning Buys 4,699 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

Replimune's RP1 Shows 33.6% Response Rate in Melanoma Trial, Marks Breakthrough | REPL Stock News - StockTitan

Nov 09, 2024
pulisher
Nov 08, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

Replimune Group Awards Stock Options, RSUs to New Employees in Retention Move | REPL Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 06, 2024

TSX Consumer Staples Capped Index (TTCS) QuotePress Release - The Globe and Mail

Nov 06, 2024
pulisher
Nov 06, 2024

KBW Bank Index (BKX) QuotePress Release - The Globe and Mail

Nov 06, 2024
pulisher
Nov 05, 2024

Itron Inc (ITRI-Q) QuotePress Release - The Globe and Mail

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group's Strategic Acquisition in Replimune Group Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 05, 2024

Teledyne Technologies Inc (TDY-N) QuotePress Release - The Globe and Mail

Nov 05, 2024
pulisher
Oct 30, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times

Oct 30, 2024
pulisher
Oct 28, 2024

Masco Corp (MAS-N) QuotePress Release - The Globe and Mail

Oct 28, 2024
pulisher
Oct 25, 2024

Skechers U.S.A. (SKX-N) QuotePress Release - The Globe and Mail

Oct 25, 2024
pulisher
Oct 24, 2024

S&P GSCI Index (GNX) QuotePress Release - The Globe and Mail

Oct 24, 2024
pulisher
Oct 23, 2024

Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 23, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Invests $251,000 in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Oct 22, 2024
pulisher
Oct 18, 2024

Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Oct 18, 2024
pulisher
Oct 16, 2024

It would be worthwhile to take a closer look at Replimune Group Inc (REPL) - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Daily Progress: Replimune Group Inc (REPL) Drop -7.06, Closing at 10.67 - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

Replimune Group Inc [REPL] Insider Selling: Time to sell? - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Replimune Group Inc Inc. (REPL) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

Replimune Group (NASDAQ:REPL) Stock Price Down 5.2%Here's What Happened - MarketBeat

Oct 14, 2024
pulisher
Oct 13, 2024

Learn to Evaluate (REPL) using the Charts - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 13, 2024

Cubist Systematic Strategies LLC Buys 53,313 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Oct 13, 2024
pulisher
Oct 09, 2024

Gaining Ground: Replimune Group Inc (REPL) Closes Higher at 11.74, Up 3.62 - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings - GuruFocus.com

Oct 07, 2024
pulisher
Oct 04, 2024

Cubist Systematic Strategies LLC Increases Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Millennium Management LLC - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Chief Financial Officer Hill Emily Luisa sale 8,938 shares of Replimune Group Inc [REPL] - Knox Daily

Oct 03, 2024
pulisher
Oct 02, 2024

Insiders At Replimune Group Sold US$863k In Stock, Alluding To Potential Weakness - Simply Wall St

Oct 02, 2024

Replimune Group Inc Azioni (REPL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Replimune Group Inc Azioni (REPL) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Sarchi Christopher
Chief Commercial Officer
Nov 18 '24
Sale
10.78
5,207
56,131
87,045
Hill Emily Luisa
Chief Financial Officer
Aug 16 '24
Sale
10.18
8,938
90,989
101,057
Xynos Konstantinos
Chief Medical Officer
Jun 07 '24
Sale
7.50
15,881
119,108
117,131
Sarchi Christopher
Chief Commercial Officer
May 16 '24
Sale
6.47
2,218
14,350
92,252
Schwendenman Andrew
Chief Accounting Officer
May 16 '24
Sale
6.47
2,298
14,868
38,238
Love Colin
Chief Operating Officer
May 16 '24
Sale
6.47
17,615
113,969
777,345
Astley-Sparke Philip
Executive Chairman
May 16 '24
Sale
6.47
37,928
245,394
1,487,350
Coffin Robert
Director
May 16 '24
Sale
6.47
11,464
74,172
1,821,872
Patel Sushil
Chief Executive Officer
May 16 '24
Sale
6.47
20,194
130,655
212,014
Xynos Konstantinos
Chief Medical Officer
May 16 '24
Sale
6.47
6,367
41,194
133,012
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):